Personalized mRNA Vaccine Shows Breakthrough Success in Preventing Skin Cancer Recurrence

A phase three clinical trial involving 1,137 patients who had undergone surgical removal of skin cancer demonstrated for the first time the efficacy of a personalized mRNA-based vaccine combined with immunotherapy in preventing cancer recurrence. Participants received up to nine doses of Keytruda alongside the tailored vaccine over approximately one year, compared to a control group treated with Keytruda alone. No new safety concerns were reported during the study.

Professor Gal Markel, director of the Davidoff Cancer Center at Beilinson Hospital and a study participant, described the results as a breakthrough, highlighting that this is the first phase three trial to prove the effectiveness of a personalized immune-activating treatment based on individual patient tumor characteristics in preventing disease relapse. The technology is also being tested in clinical trials for other cancers, including lung cancer.

The vaccine is custom-made for each patient by analyzing mutations in their tumor but, unlike cell therapies, does not require the use of the patient’s own cells, potentially simplifying production and reducing costs. Moderna CEO Stéphane Bancel noted that pricing for the treatment has not yet been set, while Dean Li, head of research and development at Merck, stated that regulatory discussions will begin soon.

Following the publication of the trial results, Moderna’s stock surged about 90% in pre-market trading, and Merck’s shares rose by 7.5%. Analysts predict the vaccine’s launch could significantly boost Moderna’s profitability, generating approximately $3 billion in revenue by 2035.